Q-omics provides the consensus-scored MIR513C profile across patient tissues and cancer cell-line models. MIR513C expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR513C is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR513C RNA expression shows 6,056 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight LIHC, and KIRC as cancer lineages where MIR513C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR513C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR513C survival associations across molecular data types. MIR513C RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR513C RNA expression–survival associations across cancer types. High MIR513C expression shows unfavorable associations in LIHC, PAAD, OV, ESCA, SARC and GBM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR513C RNA expression.
This table summarizes MIR513C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR513C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR513C shows lower tumor expression in COAD and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher MIR513C RNA expression in tumor versus normal tissue (log2 FC = +0.593, t-test p < 0.001).
This table shows molecular features associated with MIR513C in patient tissues and cancer cell lines. In patient samples, MIR513C shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
